可切除胰腺癌的判断标准与治疗及其争议

doi:10.16139/j.1007-9610.2022.01.002

摘要/Abstract

中图分类号:

R735.9

何敏, 刘颖斌. 可切除胰腺癌的判断标准与治疗及其争议[J]. 外科理论与实践, 2022, 27(01): 6-10.

HE Min, LIU Yingbin. Resectable pancreatic cancer: diagnosis criterion, treatment and controversy[J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 6-10.

参考文献 31

[1]	Siegel R, Ma J, Zou Z, et al. Cancer statistics,2014[J]. CA Cancer J Clin, 2014, 64(1):9-29. doi: 10.3322/caac.21208 URL
[2]	Margaret A, Tempero MD, Mokenge P, et al. Pancreatic adenocarcinoma,version 2.2021[J]. J Natl Compr Canc Netw, 2021, 19(4):439-457. doi: 10.6004/jnccn.2021.0017 URL
[3]	Mehta VK, Fisher G, Ford JA, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas[J]. J Gastmintest Surg, 2001, 5(1):27-35.
[4]	Tempero MA, Malafa MP, Chiorean EG, et al. Pancreatic adenocarcinoma,version 1.2019[J]. J Natl Compr Canc Netw, 2019, 17(3):202-210. doi: 10.6004/jnccn.2019.0014 URL
[5]	Loyer EM, David CL, Dubrow RA, et al. Vascular involvement in pancreatic adenocarcinoma:reassessment by thin-section CT[J]. Abdom Imaging, 1996, 21(3):202-206. pmid: 8661548
[6]	Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT[J]. Am J Roentgenol, 1997, 168(6):1439-1443. pmid: 9168704
[7]	殷允娟, 曾蒙苏, 李卉, 等. MRI对胰腺癌胰周血管侵犯的手术可切除性评价[J]. 临床放射学杂志, 2005, 24(9):792-796.
[8]	李卉, 曾蒙苏, 周康荣, 等. 胰腺癌侵犯胰周主要血管的CT表现分析[J]. 中华放射学杂志, 2005, 39(3):293-297.
[9]	Katz MH, Fleming JB. Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant the-rapy is not reflected by radiographic indicators[J]. Cancer, 2012, 8(23):5749-5756.
[10]	Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRlNOX for locally advanced and borderline resectable pancreatic cancer[J]. Ann Surg, 2015, 261(1):12-17. doi: 10.1097/SLA.0000000000000867 URL
[11]	Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy[J]. Ann Surg Oncol, 2013, 20(7):2188-2196. doi: 10.1245/s10434-012-2809-1 pmid: 23247983
[12]	Ferrone CR, Finkelstein DM, Thayer SP, et al. Periope-rative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma[J]. J Clin Oncol, 2006, 24(18):2897-2902. doi: 10.1200/JCO.2005.05.3934 URL
[13]	徐华祥, 徐帅帅, 李硕, 等. 术前血清CA125预测血清CA19-9正常胰腺癌病人术后生存的价值[J]. 中国临床医学, 2020, 27(1):50-54.
[14]	Abrams RA, Lowy AM, O′ Reilly EM, et al. Combined modality treatment of resectable and borderline resectable pancreas cancer; expert consensus statement[J]. Ann Surg Oncol, 2009, 16(7):1751-1756. doi: 10.1245/s10434-009-0413-9 pmid: 19390900
[15]	中国临床肿瘤学会胰腺癌专家委员会. 胰腺癌综合诊治中国专家共识(2014年版)[J]. 临床肿瘤学杂志, 2014,(4):358-370.
[16]	刘颖斌, 吴文广. 基于胰腺全系膜切除理念的胰头癌整块切除原则[J]. 外科理论与实践, 2015, 20(6):476-478.
[17]	刘颖斌, 吴文广. 胰头癌根治性切除的范围与争议[J]. 中华消化外科杂志, 2015, 14(8):615-618.
[18]	郝纯毅, 刘续宝, 孙备, 等. 可能切除胰腺癌治疗的现状与争议[J]. 中华消化外科杂志, 2018, 17(7):677-681.
[19]	Barenboim A, Lahat G, Geva R, et al. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer:an intention to treat analysis[J]. Eur J Surg Oncol, 2018, 44(10):1619-1623. doi: S0748-7983(18)31260-5 pmid: 30146251
[20]	Lee JL, Kim SC, Kim JH, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma[J]. Surgery, 2012, 152(5):851-862. doi: 10.1016/j.surg.2012.03.010 URL
[21]	白雪莉, 粟伟, 李想, 等. 新辅助治疗对胰腺癌术后并发症的影响[J]. 中华外科杂志, 2018, 56(11):805-808.
[22]	Mellon EA, Hoffe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic bodyradiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma[J]. Acta Oncol, 2015, 54(7):979-985. doi: 10.3109/0284186X.2015.1004367 pmid: 25734581
[23]	Le Seodan R, Mornex F, Girard N, et al. Preoperative chemoradiation in potentially reseetable pancreatic adenocarcinoma:feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review[J]. Ann Oncol, 2009, 20(8):1387-1396. doi: 10.1093/annonc/mdp015 URL
[24]	Leone F, Gatti M, Massucco P, et al. Induction gem-citabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for nemdjuvant treatment of locally advanced pancreatic cancer: a single institutional experience[J]. Cancer, 2012, 119(2):277-284. doi: 10.1002/cncr.27736 URL
[25]	Lee SE, Jang JY, Kim MA, et al. Clinical implications of immunohistochemically demonstrated lymph node micrometastasis in resectable pancreatic cancer[J]. J Korean Med Sci, 2011, 26(7):881-885. doi: 10.3346/jkms.2011.26.7.881 URL
[26]	Kim N, Han IW, Ryu Y, et al. Predictive nomogram for early recurrence after pancreatectomy in resectable pancreatic cancer: risk classification using preoperative clinicopathologic factors[J]. Cancers(Basel), 2020, 12(1):E137.
[27]	Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma(PACT-15): a randomised, open-label, phase 2-3 trial[J]. Lancet Gastroenterol He-patol, 2018, 3(6):413-423.
[28]	Motoi F, Kosuge T, Ueno H, et al. Randomized phase Ⅱ/Ⅲ trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer(Prep-02 / JSAP05)[J]. Jpn J Clin Oncol, 2019, 49(2):190-194. doi: 10.1093/jjco/hyy190 URL
[29]	Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative / neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages[J]. PLoS Med, 2010, 7(4):e1000267. doi: 10.1371/journal.pmed.1000267 URL
[30]	Marchegiani G, Andrianello S, Nessi C, et al. Neoadjuvant therapy versus upfront resection for pancreatic cancer: the actual spectrum and clinical burden of postope-rative complications[J]. Ann Surg Oncol, 2018, 25(3):626-637. doi: 10.1245/s10434-017-6281-9 pmid: 29214453
[31]	Dahdaleh FS, Naffouje SA, Hanna MH, et al. Impact of neoadjuvant systemic therapy on pancreatic fistula rates following pancreatectomy: a population-based propensity- matched analysis[J]. J Gastrointest Surg, 2021, 25(3):747-756. doi: 10.1007/s11605-020-04581-y URL

可切除胰腺癌的判断标准与治疗及其争议

Resectable pancreatic cancer: diagnosis criterion, treatment and controversy

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 31

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱颖, 汤玉茗, 黄佳, 章永平, 姚玮艳. 全反式维A酸可促进肿瘤相关诱导配体对多种胰腺癌细胞的凋亡作用[J]. 内科理论与实践, 2023, 18(03): 171-176.
[2]	杨蕊馨, 杜宇童, 燕然林, 朱正纲, 李琛, 于颖彦. 消化道肿瘤单细胞转录组测序研究中生物样本前处理改良的探索[J]. 诊断学理论与实践, 2022, 21(05): 567-574.
[3]	吴莉莉, 许耀麟, 楼文晖. 放射治疗在胰腺癌治疗中的应用现状和展望[J]. 外科理论与实践, 2022, 27(01): 25-29.
[4]	王冲, 程石. 可切除胰腺癌术前减黄的共识与争议[J]. 外科理论与实践, 2022, 27(01): 30-33.
[5]	卫积书, 黄诗朦. 胰腺癌嗜神经侵袭与神经重塑的研究历史和治疗现状[J]. 外科理论与实践, 2022, 27(01): 42-45.
[6]	李晓丽, 李为光, 钱爱华, 曹国良. 胰腺癌血清微RNA-486-3p的异常表达及对细胞增殖、凋亡的影响[J]. 内科理论与实践, 2021, 16(02): 121-125.
[7]	罗丹阳, 高益鸣. 口腔菌群与胰腺癌的相关性研究进展[J]. 外科理论与实践, 2021, 26(01): 84-86.
[8]	丁方谜, 刘振东. 叉头盒蛋白D1激活细胞外信号调节激酶通路促进胰腺癌侵袭转移[J]. 外科理论与实践, 2020, 25(06): 486-492.
[9]	钱梨寒, 沈柏用. 局部进展期胰腺癌综合治疗的研究进展[J]. 外科理论与实践, 2020, 25(05): 442-446.
[10]	吴璟奕, 李国静, 费健. 以急性胰腺炎为首发表现的胰腺癌（附17例报告）[J]. 外科理论与实践, 2020, 25(04): 326-330.
[11]	孙文韬, 邓侠兴. 胰腺癌与乙型肝炎感染的研究进展[J]. 外科理论与实践, 2020, 25(02): 171-173.
[12]	张超, 王伟艺, 唐文皓. 自噬在胰腺癌及其治疗中作用的研究进展[J]. 外科理论与实践, 2019, 24(06): 555-559.
[13]	薛美琳, 陈皓. 内镜超声检查及相关技术在胰腺癌诊治的应用[J]. 外科理论与实践, 2019, 24(06): 565-568.
[14]	严诚, 倪小艳, 姚秀忠, 陈财忠, 顾君英. 自由呼吸弥散加权磁共振成像在自身免疫性胰腺炎与胰腺癌诊断中的应用分析[J]. 外科理论与实践, 2019, 24(03): 230-235.
[15]	傅宁稹, 王伟珅, 詹茜, 沈柏用. 胰周淋巴系统概况及在胰腺癌治疗中的意义[J]. 外科理论与实践, 2019, 24(03): 276-280.